On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even in times of uncertainty. He pointed out that earnings are once again playing a significant role in driving market behavior.
“Earnings matter again, okay? That’s what happened last night when the United States and China reached an agreement, however temporary, to hold off trade armageddon. The rollback of the exorbitant tariffs to much more reasonable levels caused the stock market to explode.”
READ ALSO: 10 Jim Cramer Stocks with Huge Upside Potential and Jim Cramer’s Thoughts on These 13 Stocks.
He highlighted that the rally was not limited to companies directly tied to U.S.-China trade. He called it “a spectacular day for the bulls.” Still, Cramer was quick to ground the excitement. He pointed out that despite the dramatic gains, the S&P 500 remains essentially flat for the year. While he welcomed the reversal, he said:
“Now don’t get me wrong, I’m glad it happened, but I just spent a week in Europe, and it is stunning how much better the markets are doing over there.”
He expressed hope that the rebound in U.S. stocks continues but warned investors not to ignore other global opportunities. “If we find ourselves in trouble again, something that’s still a real possibility, please don’t forget that Europe’s also an option,” he said. He acknowledged that European markets have been the best-performing so far this year.
“Bottom line: It’s better to stay in, stay on, and let her ride than to try to pick the perfect moment to trade in and out and in and out of the stock market. By the way, that’s not much of a strategy. It’s more of a game of chicken where there are no winners, just losers who think they are smarter than the average bear.”
Our Methodology
For this article, we compiled a list of 13 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on May 12. We listed the stocks in ascending order of their hedge fund sentiment as of the fourth quarter of 2024, which was taken from Insider Monkey’s database of over 1,000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13 Stocks on Jim Cramer’s Radar Recently
13. Banco Santander, S.A. (NYSE:SAN)
Number of Hedge Fund Holders: 17
Banco Santander, S.A. (NYSE:SAN) was mentioned during the episode, and here’s what Mad Money’s host had to say:
“Long time Cramer fave, Banco Santander, which is the second-best performing in the index (IBEX 35), up almost 52% for the year. Hey, by the way, Santander’s American Deposit Receipts, SAN for you home gamers, are up almost 50% since we last spoke to Executive Chair Ana Botín back in October. Due to an embrace of technology and a knowledge of the consumer worldwide, Botín has built a powerhouse that’s the envy of Europe. They just did a really smart transaction in Poland last week… Many reasons I’m partial to Santander, symbol, SAN.”
Banco Santander (NYSE:SAN) provides a wide range of financial services, including banking, lending, mortgages, asset management, insurance, and digital payments. The company also offers corporate and investment banking, and its offerings include online financial products.
12. Harrow, Inc. (NASDAQ:HROW)
Number of Hedge Fund Holders: 20
A caller asked Cramer’s latest thoughts on Harrow, Inc. (NASDAQ:HROW), and he said:
“Look, it’s going to make money. Eye care is a good business. I don’t want to go away from it because if it makes money, then we’ll say, hey wait, wait a second, why did we get out right before the earnings breakout? So I’m okay with it.”
Harrow (NASDAQ:HROW) develops and markets a range of pharmaceutical products for eye care, including treatments for inflammation, infections, pain, and other ophthalmic conditions. The company’s offerings include compounded medications, gels, drops, injections, and emulsions used in various eye-related therapies. On May 12, Craig-Hallum analyst Chase Knickerbocker reduced the price target on HROW to $54 from $58 but maintained a Buy rating after the company missed Q1 earnings expectations. Revenue came in at $47.8 million compared to the Street estimate of $57.0 million, and adjusted EBITDA was $1.9 million versus $11.9 million expected.
The firm cited headwinds from complex destocking and GTN factors. Iheezo fell short due to greater-than-anticipated distributor inventory reductions, and anterior segment products were impacted by previous under accruals. The compounding business also missed projections. On a positive note, Vevye exceeded internal goals and is projected to generate around $100 million for the year.
